title: Choosing a treatment for patients at the time a fracture is presented.
abstract: The occurrence of a fragility fracture is an opportunity to recognize osteoporosis and begin treatment to reduce the risk of another fracture. However, selecting the treatment may have an impact on the incident fracture and this requires careful consideration of the patient and the treatment choices. There is no consensus regarding the management of osteoporosis at the time of an incident fracture. This review will consider the treatment options after a fragility fracture.
authors.affiliation: Divisions of Rheumatology, Allergy & Immunology, Vanderbilt University Medical Center, Nashville, TN 37203, USA. bobo.tanner@vanderbilt.edu
authors.forename: S Bobo
authors.initials: SB
authors.lastname: Tanner
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000150:complications* / Q000188:drug therapy*; D053245:RANK Ligand / Q000627:therapeutic use; D055502:Secondary Prevention; D019379:Teriparatide / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D053245:RANK Ligand; D019379:Teriparatide; D000069448:Denosumab